JS 201
Alternative Names: JS-201Latest Information Update: 25 Sep 2021
At a glance
- Originator Shanghai Junshi Biosciences
- Developer Hunan Province Tumor Hospital; Shanghai Junshi Biosciences
- Class Antineoplastics; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Programmed cell death-1 receptor antagonists; Transforming growth factor beta inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Small cell lung cancer
- Phase I Solid tumours
Most Recent Events
- 30 Jun 2021 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater, In adults, In the elderly) in China (Parenteral) (NCT04956926)
- 01 Jun 2021 Phase-II clinical trials in Small cell lung cancer (Second-line therapy or greater, Combination therapy) in China (IV) (NCT04951947)
- 07 Mar 2021 Shanghai Junshi Biosciences plans a clinical trial for Solid tumours in China